|
NICE (UK) issues further draft guidelines for use of sofosbuvir within the NHS
(Preview)
NICE (the National Institute for Health and Care Excellence) consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C15th Aug. 2014 - In further draft guidance NICE has recommended sofosbuvir (Sovaldi, Gilead Sciences) as a treatment option for some people w...
|
Cinnamon Girl
|
0
|
1038
|
|
|
|
|
GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH HEPATITIS C INFECTION
(Preview)
If you haven't seen the April 2014 WHO (World Health Organization) HCV care and treatment guidelines, I thought you may be interested in reading their recommendations. There is a lot of interesting information. I looked for it's previous inclusion here on the forum and didn't see it. I apologize if...
|
Tig
|
4
|
1296
|
|
|
|
|
UNC Study on Viral Persistence
(Preview)
Might be of interest to some. Such a sneaky little bastard... UNC Hep C Study
|
OldenSlow
|
4
|
1228
|
|
|
|
|
New Clinical Study Info
(Preview)
Hi, Just got this in my email and thought I'd pass it on. Looks like it is going to be used to monitor patients doing the Sovaldi/Olysio combo for information on how the drug is doing in general population.This email is to inform you about a clinical study of patients with chronic Hepatitis C. The purpo...
|
suziq
|
0
|
839
|
|
|
|
|
August Edition- HCV Advocate newsletter
(Preview)
Hi all, Here's the latest Newsletter. Some observations: The suggestion to limit caffeine to decrease headaches and insomnia is interesting, in view of a recent post about coffee consumption. Do your own research! Mixed cryoglobulinaemia is certainly found in some HCV patients. However, the va...
|
mallani
|
4
|
1975
|
|
|
|
|
July Newsletter- HCV Advocate
(Preview)
Here is the July Newsletter from the HCV Advocate website. ww.hcvadvocate.org/news/newsLetter/2014/advocate0714.html
|
mallani
|
0
|
1513
|
|
|
|
|
Motley fool //
(Preview)
Recs Back to Yahoo!Are Insurers Playing Fair With HIV Patients?By Todd Campbell | More Articles | Save For Later July 20, 2014 | A new complaint claims that insurers may be flouting a key provision of the Affordable Care Act that prevents discrimination. As part of health-care insur...
|
Huey
|
0
|
908
|
|
|
|
|
FibroScans now Available in US
(Preview)
Not a question, but just an update on the FibroScan technology in the US which is a non-invasive method to measure fibrosis staging (replacing the needle biopsy). In 2013 the FDA approved the FibroScan technology and in 2014 the AASLD endorsed the FibroScan technology. The FibroScan is technicall...
|
Luckydog1953
|
7
|
2274
|
|
|
|
|
New HIV Drugs are now covered by obomacare
(Preview)
http://www.fool.com/investing/general/2014/07/13/obamacares-surprising-hiv-drug-demand.aspx
|
Huey
|
0
|
859
|
|
|
|
|
Japan Approves First All-Oral, Ribavirin-Free Hep C Treatment, Daklinza (daclatasvir) and Sunvepra (asunaprevir)
(Preview)
Monday, July 7, 2014. PRINCETON, N.J. Bristol-Myers Squibb Company announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra(asunaprevir), a NS3/...
|
Cinnamon Girl
|
2
|
1585
|
|
|
|
|
BMS Receives Positive CHMP Opinion for daclatasvir (`Daklinza`) in the EU
(Preview)
PRINCETON, N.J.-- 27 June, 2014. Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS...
|
Cinnamon Girl
|
1
|
1398
|
|
|
|
|
Australia New Zealand - TGA approves Gilead's Sovaldi
(Preview)
http://hepatitiscnewdrugs.blogspot.com/2014/07/hepatitis-c-news-australia-new-zealand.html
|
OldenSlow
|
6
|
1850
|
|
|
|
|
Researchers extend liver preservation for transplantation
(Preview)
http://hepatitiscnewdrugs.blogspot.com/2014/06/nih-funded-researchers-extend-liver.html
|
OldenSlow
|
1
|
1031
|
|
|
|
|
T-cells
(Preview)
http://news.yahoo.com/designer-t-cells-fight-viruses-transplants-191027539.html
|
Huey
|
2
|
1230
|
|
|
|
|
US Gov't to Investigate High Price of Sovaldi
(Preview)
The people who run the IRS, Post Office, VA, ACA, Medicare are now involved - I feel so much better that this is going to be resolved SOON! longld The $84,000 Price Tag On Gilead's Hepatitis C Treatment Sovaldi Has Evoked Sharp Criticism From Several Quarters. The drug was released in January and sin...
|
longld
|
1
|
1019
|
|
|
|
|
AbbVie All-Oral Hep C Therapy gets Rapid EU Review
(Preview)
(Reuters) - European regulators have validated AbbVie's application for an experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus and the therapy is now under accelerated assessment. The U.S. drugmaker said on Tuesday the move by the European Med...
|
Cinnamon Girl
|
0
|
1175
|
|
|
|
|
U.S. FDA Grants Priority Review to AbbVie for Investigational All-Oral Therapy for the treatment of Gen 1
(Preview)
June 13, 2014 AbbVie announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (F...
|
Cinnamon Girl
|
0
|
824
|
|
|
|
|
Sovaldi is going to be paired up with other DAA's to shorten the time on treatment.
(Preview)
n the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks. Bristol-Myers disclosed plans for the exploratory 30-patient t...
|
Huey
|
1
|
1109
|
|
|
|
|
New Four Week Treatment to Start Testing
(Preview)
It just keeps getting BETTER and BETTER !!! Exclusive: A four-week hep C cure? Bristol to test drugs with Gilead's Sovaldi SuziQ
|
suziq
|
0
|
878
|
|
|
|
|
USA Ranks last in Health Care.
(Preview)
.Source: The Commonwealth Fund Lead author Karen Davis, of Johns Hopkins Bloomberg School of Public Health, says the findings were disappointing, but not surprising. This is the fifth time in a row that the U.S. has landed at the bottom of the heap in the semi-annual report, in large part due to the f...
|
Huey
|
3
|
1472
|
|
|
|
|
NICE (UK) consults on draft guidance on the drug sofosbuvir (Sovaldi)
(Preview)
In draft recommendations published on 16th June 2014 healthcare guidance body NICE (the National Institute for Health and Care Excellence) is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C.Commenting on the draft guid...
|
Cinnamon Girl
|
2
|
1667
|
|
|
|
|
June 2014 HCV Advocate Newsletter
(Preview)
website...http://www.hcvadvocate.org/news/newsLetter/2014/advocate0614.html
|
Cinnamon Girl
|
2
|
1023
|
|
|
|
|
Scottish Medical Consortium advise restricted access to sofosbuvir on NHS in Scotland
(Preview)
The Scottish Medicines Consortium (SMC) has today published its advice on the use of the drug sofosbuvir on the NHS in Scotland. The body of experts have "accepted sofosbuvir for restricted use in patients with genotypes 1 to 6."The SMC go on to make the following specific restrictions:Use in treat...
|
Cinnamon Girl
|
7
|
1525
|
|
|
|
|
Merck is buying Idenix - More new drugs???
(Preview)
http://www.marketsemerging.com/2-stocks-everyone-is-talking-about-idenix-pharmaceuticals-inc-nasdaqidix-international-game-technology-nyseigt/179394/
|
Jener
|
0
|
888
|
|
|
|
|
Quebec Approves Sovaldi Reimbursement
(Preview)
Priority Review by INESSS Provides Recommendation to Treat Patients with Genotypes 1 and 4 HCV Infection Regardless of Fibrosis Level Montreal, June 2, 2014 /CNW/ - "Gilead Sciences Canada, Inc. is pleased to announce that the Health and Social Services Ministry has placed Sovaldi® (s...
|
OldenSlow
|
3
|
1831
|
|
|
|
|
Clinical trials started for TT-034 an injectable hcv tx.
(Preview)
Pretty interesting article about new clinical trial involving one injection of TT-034. SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) announced that it has dosed the first patient in its 'first in man', Phase I/IIa clinical tria...
|
maddie
|
0
|
972
|
|
|
|
|
Link to a news flash
(Preview)
http://www.hepmag.com/articles/south_carolina_hepatitis_b_lawsuits_2831_25641.shtml
|
Huey
|
0
|
1103
|
|
|
|
|
Sofosbuvir Based Hepatitis C Clinical Trials - Recruiting
(Preview)
recruiting...http://hepatitiscnewdrugs.blogspot.co.uk/2014/05/updates-sofosbuvir-based-hepatitis-c.html
|
Cinnamon Girl
|
0
|
1129
|
|
|
|
|
Medicare Eases Restrictions On Pricey Hepatitis C Treatment
(Preview)
"The shift has come about because of an Arizona man named Walter Bianco who was twice denied Medicare coverage for two new drugs that together cost about $150,000. But those denials were reversed this week after Shots and NPR's Morning Edition reported on Bianco's case. Bianco has been infe...
|
OldenSlow
|
5
|
2290
|
|
|
|
|
Simeprevir approved in the European Union for the treatment of adults with hep C genotype 1 and 4
(Preview)
Press Release, Stockholm, Sweden - Medivir AB announces that simeprevir has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C in combination with other medicinal products.OLYSIO (Simeprevir) provides a...
|
Cinnamon Girl
|
0
|
976
|
|
|
